Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation

ConclusionThese findings support the biosimilarity of AGABIO in comparison with agalsidase beta. The clinical study phase is currently under development.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research